Last reviewed · How we verify

NCT06863181

Comparison of Conventional and Cooled Radiofrequency Ablation in Knee Osteoarthritis

Completed NA Last updated 27 February 2026
What this trial tests

NA trial testing Radiofrequency ablation in Knee Osteoarthritis in 26 participants. Completed in 12 November 2025.

Timeline
1 February 2025
Primary endpoint
12 August 2025
12 November 2025

Quick facts

Lead sponsorGaziler Physical Medicine and Rehabilitation Education and Research Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment26
Start date1 February 2025
Primary completion12 August 2025
Estimated completion12 November 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Who can join

Adults 50 to 80, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to examine and compare the effects of conventional and cooled radiofrequency ablation on pain and disability levels in patients with knee pain resistant to other treatments due to knee osteoarthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Radiofrequency ablation

Trials testing the same drug.

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Other Gaziler Physical Medicine and Rehabilitation Education and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing